Milbemycin Oxime is chemically Mixture of (2aE,2′R,2a1S,4E,5′S,6R,6′R,8E,11R,15S,17aR,20Z,20aR)-6′-ethyl-2a1-hydroxy-20-(hydroxyimino)-5′,6,8,19-tetramethyl-2a1,3′,4′,5′,6,6′,7,10,11,14,15,17a,20,20a-tetradecahydrospiro[2H,17H-11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2′-pyran]-17-onand (2aE,2′R,2a1S,4E,5′S,6R,6′R,8E,11R,15S,17aR,20Z,20aR)-2a1-hydroxy-20-(hydroxyimino)-5′,6,6′,8,19-pentamethyl-2a1,3′,4′,5′,6,6′,7,10,11,14,15,17a,20,20a-tetradecahydrospiro[2H,17H-11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2′-pyran]-17-one (as per EP). It is also known as Mixture of Milbemycin A4 oxime & Milbemycin A3 oxime (EP). Milbemycin Oxime is supplied with detailed characterization data compliant with regulatory guideline. Milbemycin Oxime can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Milbemycin.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.